

MEDIA RELEASE • MEDIA RELEASE • MEDIA RELEASE

IRE Elit, subsidiary of The Institute for Radioelements, and Eczacıbaşı-Monrol Nuclear Products, signed a distribution agreement for *Galli Eo*TM, the new ⁶⁸Ge/⁶⁸Ga generator to cover almost 40 countries in the world.

Fleurus, Belgium & Istanbul Turkey October 20th, 2015 – After a successful launch at the European Academy of Nuclear Medicine Congress and with the ambition to distribute its high potential generator *Galli Eo*TM worldwide, IRE ELiT has signed with Eczacıbaşı-Monrol, leader in Turkey's nuclear medicine market, a distribution agreement to cover almost 40 countries in the Middle East, north Africa and central Europe.

Both companies expressed enthusiasm on this agreement:

“Eczacıbaşı-Monrol is very excited about this new collaboration with IRE-Elit. ⁶⁸Ga Generator will be a very valuable and good fit to Eczacıbaşı-Monrol's product portfolio and future strategies. We believe that, with this innovative product, we will be highly beneficial for the healthcare professionals and especially for patients having a better access to diagnose of their diseases.”, were the words of **Eczacıbaşı-Monrol business development team**.

On the other hand, **Jean- Michel Vanderhofstadt, CEO at IRE ELiT** said: *“We have already been working with Monrol for a few years as part of our radiochemical activities and we really thought that Monrol, thanks to its leadership and market knowledge, was the distributor of choice to cover these distant territories that we know relatively little. This dynamic team and the shared excitement around gallium which cannot do else but unite us.”*

About IRE – IRE ELiT

IRE, or Institute for Radioelements was created in 1971 as a public utility foundation. Its main activity is the production of radioisotopes for diagnostic and treatment applications in the field of nuclear medicine. More than six million nuclear medicine examinations are carried out every year thanks to medical radioisotopes produced by IRE. IRE ELiT was created in 2010 as a subsidiary of the IRE and produces several radiopharmaceutical products used in the diagnosis and treatment of certain cancers and in palliative care. Headquartered in Fleurus, Belgium, IRE ELiT employs approximately 180 full-time-equivalent associates. For more information, please visit <http://www.ire.eu>

About Eczacıbaşı-Monrol Nuclear Products

Eczacıbaşı-Monrol Nuclear Products, an equal share joint venture between Bozlu Holding and Eczacıbaşı Holding companies that was established in 2008, serves for the development nuclear medicine market through the production of high-quality radiopharmaceuticals for diagnosis and treatment. In addition to organic growth in Turkey and abroad, Eczacıbaşı-Monrol has expanded its operations and product portfolio through the acquisition of Mol-Image in 2011 and Capintec in 2012.

Media Relations

For multimedia content supporting this press release, please contact:

- IRE ELiT: **Bérénice Pignol** *Product Manager* -T. +32 (0)71 82 9493
F.+32 (0)71 81 3812 - M. +32 (0)471 70 62 44 - Berenice.Pignol@ire-elit.eu

- Eczacıbaşı-Monrol :**Metehan Karamollaoglu** *Marketing Manager* -T. +90 216 544 05 44
F. +90 216 472 41 41-M. +90 532 254 42 20 - metehan.karamolla@monrol.com